Palliative Care Use and Patterns of End-of-Life Care in Hospitalized Patients With Calciphylaxis

Affiliations

¹ Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: kolaniran@mgh.harvard.edu.
² Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
³ Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Summer M. Redstone Burn Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁶ Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁷ Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Palliative and Advanced Illness Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Kabir O Olaniran et al. J Pain Symptom Manage. 2019 Feb.

. 2019 Feb;57(2):e1-e3.

doi: 10.1016/j.jpainsymman.2018.10.514. Epub 2018 Nov 3.

¹ Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: kolaniran@mgh.harvard.edu.
² Division of Nephrology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
³ Division of Palliative Care and Geriatric Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁴ Summer M. Redstone Burn Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁶ Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁷ Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Medicine, Palliative and Advanced Illness Research Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

No abstract available

References

1. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. Ingelfinger JR, ed. N Engl J Med. 2018;378(18):1704–1714. doi:10.1056/NEJMra1505292. - DOI - PubMed
1. Weenig RH, Sewell LD, Davis MDP, McCarthy JT, Pittelkow MR. Calciphylaxis: Natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56(4):569–579. doi:10.1016/J.JAAD.2006.08.065. - DOI - PubMed
1. Riemer CA, el-Azhary RA, Wu KL, Strand JJ, Lehman JS. Underreported use of palliative care and patient-reported outcome measures to address reduced quality of life in patients with calciphylaxis: a systematic review. Br J Dermatol. 2017;177(6):1510–1518. doi:10.1111/bjd.15702. - DOI - PubMed
1. Wachterman MW, Pilver C, Smith D, Ersek M, Lipsitz SR, Keating NL. Quality of End-of-Life Care Provided to Patients With Different Serious Illnesses. JAMA Intern Med. 2016;176(8):1095. doi:10.1001/jamainternmed.2016.1200. - DOI - PMC - PubMed
1. Liao KP, Cai T, Gainer V, et al. Electronic medical records for discovery research in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2010;62(8):1120–1127. doi:10.1002/acr.20184. - DOI - PMC - PubMed